Background

Calcium infusion and hypotension have been described as the most important risk factors for pancreatic injury after cardiopulmonary bypass.

Methods: Rats were randomly allocated to three experimental groups undergoing either sham operation and saline infusion (Control, n = 30), hemorrhagic reduction of mean arterial pressure to 30 mmHg for 30 min alone (hypotension, n = 51), or hypovolemic hypotension followed by bolus infusion of CaCl2(200 mg *symbol* kg sup -1; hypercalcemia, n = 85). Serum ionized calcium, amylase activity, trypsinogen activation peptide in pancreatic tissue homogenates, pancreatic wet/dry weight ratio, histologic changes, and mortality were assessed for 24 h.

Results: Control rats showed no significant changes of any parameter throughout the experiments. In contrast, hypotension significantly increased serum amylase (P < 0.001), tissue trypsinogen activation peptide (P < 0.01), wet/dry weight ratio (P < 0.001), and histologic scores for edema (P < 0.001) and pancreatic necrosis (P < 0.05). Subsequent CaCl2administration transiently increased [Calcium2+](P < 0.001) with the concentration rapidly returning to baseline within 3 h. That infusion of CaCl2further increased amylase (P < 0.05), tissue trypsinogen activation peptide (P < 0.05), wet/dry weight ratio (P < 0.001), and histologic evidence of pancreatic edema (P < 0.05) and acinar necrosis (P < 0.05) when compared with hypotension alone. Whereas all Control animals survived the experiments, 22%(P < 0.05) and 47%(P < 0.05 vs. hypotension) of animals died in the hypotension and hypercalcemia groups, respectively.

Conclusions: Temporary hypotension alone causes ectopic trypsinogen activation and lethal acute pancreatitis. Superimposed hypercalcemia significantly aggravates hypotension-induced pancreatic injury and mortality in rats. (Key words: Ions: calcium; hypercalcemia. Cardiopulmonary bypass. Hypovolemic hypotension. Pancreas: acute pancreatitis; trypsinogen activation.)

ACUTE pancreatitis is a well-recognized complication after cardiopulmonary bypass (CPB). Although diagnosed infrequently, it assumes clinical importance because of the frequency of CPB procedures and its association with an unfavorable clinical course and mortality as great as 86%. Evidence of acute pancreatitis in approximately 25% of autopsies of patients dying after cardiac surgery further underlines the relevance of this complication. Several causative factors have been described, including hypothermia, non-pulsatile blood flow, complement activation, and pancreatic ischemia. Considering the well-described pathogenetic role of ischemia in acute pancreatitis many authors have suggested pancreatic ischemia, which results from temporary hypotension during CPB, as a primary factor for pancreatic complications after CPB. A recent prospective clinical study suggested administration of a large dose of calcium during separation from CPB is an equally significant risk factor. Large calcium doses are routinely administered in many centers during emergence from CPB because serum [Calcium2+] can decrease during CPB and postoperative cardiovascular function can benefit from the inotropic and vasopressor effects of calcium. However, other studies reported that the serum ionized calcium concentration does not change or even increases during CPB and that calcium infusion is not beneficial and may in fact adversely affect postoperative cardiac recovery. Based on these conflicting data, the routine administration of calcium salts after CPB is still openly discussed. Because the risk for postoperative pancreatic complications would principally influence the indication for routine calcium administration, we investigated the effect of calcium infusion on the ischemic pancreas with emphasis on ectopic protease activation, which is thought to be a critical event in the pathophysiology of pancreatitis. We hypothesized that the administration of calcium chloride to rats subjected to hemorrhagic hypotension would worsen pancreatic injury and exacerbate mortality.

Experimental Protocol

Experiments were carried out according to National Institutes Health guidelines for the care and use of laboratory animals and approved by the Subcommittee on Research Animal Care of Massachusetts General Hospital. Male Sprague-Dawley rats (weighing 260–360 g) were obtained from Charles River Laboratories (Wilmington, MA). Anesthesia was initiated with vaporized ether and maintained by intraperitoneal injections of 20 mg *symbol* kg sup -1 pentobarbital (Anpro Pharmaceuticals, Arcadia, CA) and 40 mg *symbol* kg sup -1 intramuscular ketamine (Ketalar, Parke-Davis, Morris Plains, NJ). On the day before the experiment, a polyethylene catheter (Intramedic, ID 58 mm, Clay Adams, Parsippany, NJ) was introduced into the left internal carotid artery and advanced into the aorta for blood sampling, infusions, and monitoring of arterial pressure. The catheter was tunneled subcutaneously to the suprascapular region and brought out through a steel tether, allowing unrestrained activity of the animal. Animals were then allowed to stabilize and fasted overnight with water ad libitum. The next day, animals were randomly allocated to a Control group receiving no further treatment (n = 30), hypotension group undergoing reduction of mean arterial pressure to 30 mmHg for 30 min by controlled hemorrhage via the arterial catheter, and subsequent reinfusion of the heparinized blood (Elkins-Sinn, Cherry Hill, NJ, 75 U/ml; n = 51) and a hypercalcemia group in which the hypotensive period and reinfusion was followed by a bolus injection of 200 mg *symbol* kg sup -1 CaCl2over 2 min (n = 85). Mean arterial pressure and heart rate were monitored using an Electrodyne ST-219 transducer (Becton-Dickinson, Parsippany, NJ).

Assays

Serum ionized calcium concentration was measured with an ion-selective electrode (Nova 2, Nova Biomedical, Waltham, MA) after reinfusion of the withdrawn blood (baseline), 5 min, 20 min, 1 h, 3 h, 6 h, and 24 h. Concentrations of serum amylase were determined at baseline, 20 min, 6 h, and 24 h according to the method of Ceska et al. Electrophoretic separation of serum amylase isoenzymes was performed in 7% polyacrylamide gel (pH 8.3). Serum samples were compared to secretions obtained by direct aspiration from the pancreatic and salivary ducts of control animals. Control serum was included in every experiment and all specimens were run in duplicate. After completion of electrophoresis, amylase activity was assayed in sequential segments of the gel using a previously described calorimetric technique. .

For measurement of trypsinogen activation peptide (TAP) concentrations in pancreatic tissue animals were killed at baseline, 1, 6, and 24 h, the pancreas resected, and two tissue portions (0.18–0.35 g) excised. Specimens were immersed in 0.2 M tris(hydroxymethyl)aminomethane-hydrochloride buffer (pH 7.3) containing 20 mM ethylenediaminetetraacetic acid and remaining protease activity immediately denatured by heat (100 degrees Celsius for 15 min). Each sample was then homogenized in a Brinkman Polytron (Brinkman Instruments, Westbury, NY) for 30 s with subsequent centrifugation (1,500 rpm, 10 min, 4 degrees Celsius). The resulting supernatants were coded, and stored at -20 degrees Celsius until assayed. Samples were simultaneously assayed for free TAP using a competitive enzyme-linked immunosorbent assay. .

Wet/Dry Weight Ratio

At the designated time points (baseline, 1, 6, and 24 h) the entire gland was resected in a standardized fashion by the same investigator, trimmed of fat, blotted dry, and weighed. Pancreatic water content was determined by calculating the ratio of the initial weight of the pancreatic specimen (wet weight) to its weight after incubation at 210 degrees Celsius for 12 h (dry weight).

Histopathologic Analysis

Specimens of pancreatic tissue from each time point were fixed in 10% phosphate-buffered formalin (pH 7.5), embedded in paraffin, and stained with hematoxylin and eosin for evaluation by light microscopy. The extent of interstitial edema formation, acinar cell necrosis, parenchymal hemorrhage, and inflammatory infiltration was quantitated by a pathologist unaware of the identity of the specimens using a previously described scoring system (range 0–4). .

Statistical Analysis

The results are presented as mean plus/minus SEM of at least five different experiments in each group at each time point. Differences between experimental groups were tested with one-way analysis of variance directly or after calculating the area under the curve (when multiple time points were obtained), using Student's t test with Bonferroni correction for individual differences. Statistical significance of changes from baseline values within one experimental group was investigated by paired Student's t test. Proportional differences between the individual groups were tested by chi2analysis. Differences were considered significant if P values of < 0.05 were obtained.

Circulatory Parameters, Serum Ionized Calcium

Mean arterial pressure of all animals before hemorrhage averaged 121 plus/minus 7 mmHg without significant differences between experimental groups. The average blood volume withdrawn to achieve 30 mmHg was 9.4 plus/minus 0.5 ml (hypotension) and 8.8 plus/minus 0.4 ml (hypercalcemia; 49 plus/minus 3% and 46 plus/minus 2% of estimated circulating blood volume, respectively). After reinfusion of the withdrawn blood mean arterial pressure returned to 110 plus/minus 10 mmHg in hypotensive and 107 plus/minus 13 mmHg in hypercalcemic animals after 30 min. Subsequent injection of CaCl2in the hypercalcemia group transiently increased mean arterial pressure to 142 plus/minus 15 mmHg at 5 min (P < 0.01), and mean arterial pressure remained increased after 30 min (133 plus/minus 12 mmHg, P < 0.05). Serum ionized calcium concentration after reinfusion of the withdrawn blood was 1.1 plus/minus 0.1 mmol *symbol* l sup -1. The CaCl2bolus induced an immediate increase of [Calcium2+] to 3.1 plus/minus 0.2 mmol *symbol* l sup -1 after 5 min (P < 0.001), which decreased to 2.0 plus/minus 0.1 mmol *symbol* l sup -1 after 20 min (P < 0.001 vs. baseline and 5 min) and to baseline concentrations (1.2 plus/minus 0.1 mmol *symbol* l sup -1) within 3 h.

Serum Amylase Concentration and Isoenzyme Pattern

The serum amylase concentration in control animals remained constant during the experimental period (52 plus/minus 5 U *symbol* l sup -1). In contrast, temporary hypotension immediately increased serum amylase at 20 min (103 plus/minus 5 U *symbol* l sup -1, P < 0.05), and further to 156 plus/minus 21 U *symbol* l sup -1 (P < 0.001) at 24 h. Addition of temporary hypercalcemia significantly increased serum amylase activity at 20 min above that brought about by hypotension alone (134 plus/minus 11 U *symbol* l sup -1, P < 0.05). Concentrations at 24 h were still increased but not significantly different between the hypotension and hypercalcemia groups (Figure 1). Electrophoretic analysis of the serum amylase isoenzyme pattern demonstrated that the observed increase of serum amylase activity was caused by isoamylases originating from the pancreas (data not shown).

Ectopic Trypsinogen Activation

Concentration of TAP in pancreatic tissue homogenates of controls remained unchanged (83 plus/minus 5 nmol *symbol* sup -1 *symbol* g sup -1) throughout the experimental period (Figure 2). Temporary hypotension caused an increase of TAP concentrations at 6 h (299 plus/minus 45 nmol *symbol* l sup -1 *symbol* g sup -1, P < 0.01) that was maintained until 24 h (355 plus/minus 77 nmol *symbol* l sup -1 *symbol* g sup -1, P < 0.001). Superimposing calcium infusion resulted in increased intrapancreatic trypsinogen activation at 1 h (243 plus/minus 35 nmol *symbol* l sup -1 *symbol* g sup -1, P < 0.05 vs. hypotension at 1 h) while later changes were not significantly different from the hypotension group (F2-17).

Morphology and Histopathology

Macroscopic edema formation was absent in control preparations throughout the experiments (wet/dry weight ratio 2.3 plus/minus 0.2). Temporary hypotension induced a significant increase of wet/dry weight ratio to 3.2 plus/minus 0.3 at 1 h (P < 0.001) and 4.4 plus/minus 0.6 at 24 h (P < 0.001). When calcium was administered, edema formation was significantly increased as reflected by a wet/dry weight ratio of 5.1 plus/minus 0.2 after 1 h (P < 0.001 vs hypotension). The wet/dry weight ratio remained increased until 24 h (Figure 3). Light microscopy demonstrated normal pancreatic histologic appearance in the sham-operated animals. Histologic changes induced by hemorrhagic hypotension included interstitial edema formation at 1 h (P < 0.001), patchy acinar necrosis at 24 h (P < 0.05)(Figure 4), hemorrhage (11% of specimens), inflammatory infiltration (14%) and scattered vacuolar degeneration of acinar cells. Superimposed hypercalcemia significantly increased scores for edema at 1 h (P < 0.001) and necrosis at 24 h (P < 0.001)(F4-17), whereas inflammatory infiltration (33%), hemorrhage (42%), and vacuole formation increased only nonsignificantly compared to hypotension.

Mortality

The observed morphologic and biochemical changes were associated with an increased mortality. While all control animals survived the experiments, 24-h mortality was 22%(P < 0.05) in hypotensive animals. When temporary hypotension was combined with calcium infusion mortality was significantly further increased to 47%(P < 0.05 hypercalcemia vs. hypotension).

Despite their importance for postoperative morbidity and mortality, the mechanisms responsible for development of pancreatic injury after CPB are still poorly understood. It is well established that systemic arterial pressure decreases markedly during CPB ; hypotension, in turn, significantly reduces blood supply to the pancreas with marked impairment of capillary perfusion and microcirculatory decompensation. Owing to the known sensitivity of the pancreas to the effects of hypoperfusion many authors have proposed pancreatic ischemia as the primary mechanism for pancreatic injury after CPB. We have previously demonstrated that temporary hypovolemic hypotension alone can induce the morphologic changes of necrotizing pancreatitis along with increased ectopic trypsinogen activation, which is believed to be a critical step in the pathophysiology of acute pancreatitis. A recent prospective study suggested that infusion of high CaCl2doses after CPB represents an equally important risk factor for "postpump" pancreatic injury, but was unable to establish causality. In the current study, we address this question. Because the conditions of CPB cannot be replicated in the rat, we chose as an experimental paradigm that of hemorrhagic shock, which has been shown to cause decreased pancreatic perfusion and pancreatitis. We compared the effect on the pancreas of temporary hypovolemic hypotension alone or in conjunction with bolus infusion of calcium to simulate the clinical sequence of events during CPB.

The observed effects of systemic hypotension on serum amylase activity, ectopic trypsinogen activation, and pancreatic morphology in this study are similar to those we described previously as a consequence of pancreatic ischemia. However, in the current study, subsequent administration of CaCl2significantly accelerated and accentuated the development of the hallmarks of pancreatic injury, resulting in a significantly increased mortality. Previous studies have attributed ischemia-induced hyperamylasemia and pancreatic edema formation to the generation of oxygen-derived free radicals during reperfusion. This theory is consistent with the observed early onset of the ischemia-induced changes in the current study because most of the free radical formation occurs within the first few minutes after reperfusion. Intracellular Calcium2+ accumulation, which also occurs within the initial reperfusion phase, is believed to be a critical event in ischemia/reperfusion-induced tissue damage. Reperfusion-induced elevation of intracellular [Calcium2+] is likely further increased by the acute elevation of blood ionized calcium because hypercalcemic environments increase acinar [Calcium2+]. In addition, calcium infusion induces release of cholecystokinin, which also causes a hormone-mediated increase of cytosolic calcium in acinar cells. In recognition of the deleterious effect of Calcium sup 2+ accumulation in ischemic cells, the additive effect of elevated environmental calcium could be expected to aggravate ischemia-induced pancreatic damage, an adverse effect of calcium infusion that has already been described in postischemic myocardium. .

CaCl2injection also significantly augmented intrapancreatic generation of TAP. Observations in both human and experimental pancreatitis suggest that premature intrapancreatic activation of digestive enzyme precursors represents an initiating event in the development of acute pancreatitis. Generation of trypsin plays a pivotal role in the activation process of pancreatic proteases due to trypsin's autocatalytic activity and ability to initiate the rest of the pancreatic enzyme cascade. Under physiologic conditions, TAP is cleaved from trypsinogen by enterokinase in the intestinal lumen and subsequently is degraded by mucosal peptidases. However, when ectopic intrapancreatic activation occurs, TAP provides a quantitative index of active trypsin generation that correlates with the severity of pancreatic damage. Under the conditions of this study, a small amount of TAP is found in pancreatic tissue at baseline, but these levels remained unchanged in controls throughout the experiments and are believed to represent minor physiologic autoactivation that occurs in the normal pancreas. In contrast, pancreatic TAP concentration increased continuously after hypotension, and, as with amylase release and edema formation, CaCl2further accelerated the ischemia-induced generation of TAP in pancreatic tissue.

Because several studies have demonstrated that increased calcium concentrations increase trypsinogen autoactivation, increased cytosolic [Calcium2+] in the ischemic acinar cells has been suggested as the mechanism of the ischemia-induced increase of trypsinogen activation. Calcium is an essential cofactor in trypsinogen autoactivation. It enhances the stability and activity of trypsin by binding to the N-terminal aspartyl residues of trypsinogen activation peptides, thereby abolishing their inhibitory effect on autocatalytic activation. Increased Calcium2+ accumulation in acinar cells as a consequence of ischemia and subsequent hypercalcemia could therefore contribute to the observed acceleration of TAP generation. Preliminary data from our laboratory demonstrates that hypercalcemia alone increases acinar [Calcium2+], which in turn can increase in vivo and in vitro intracellular trypsinogen activation. .

Temporary hypovolemic hypotension alone induced only patchy acinar cell necrosis. Similarly, hypercalcemia alone has been shown to produce only minimal pancreatic necrosis. However, when calcium infusion is superimposed on the ischemic pancreas, widespread necrosis of the gland results. Previous studies have indicated that the severity of acinar necrosis is related to the extent of microcirculatory impairment. As previously demonstrated, hypotension impairs pancreatic capillary perfusion by precapillary vasoconstriction, arteriovenous shunting, intracapillary clotting, and venous stasis. Because hypercalcemia can promote platelet aggregation and blood coagulation and decreases erythrocyte deformability through the Gardos effect, it could foster further microcirculatory deterioration. Calcium-induced stimulation of precapillary resistance effectors could also contribute to the compromise of pancreatic capillary flow, an effect whose importance for progression to pancreatic necrosis has been shown for other therapeutic vasoconstrictors. .

Temporary hypotension itself caused death in 22% of animals. The prevalence of fatal outcome was more than doubled when calcium infusion was added to the initial ischemic insult. Inasmuch as preliminary experiments demonstrated that comparable infusions of CaCl2alone are not lethal, these data illustrate the potentially serious consequences of calcium administration if the pancreas is already primed and susceptible because of an ischemic lesion.

The rats in this experimental study were normocalcemia after the period of hypovolemic hypotension and before the calcium infusion. While it could be argued that many patients after CPB are hypocalcemic (and thus presumably less susceptible to the development of hypercalcemia with calcium administration), an inevitable transient hypercalcemia will occur whenever calcium is given as a bolus as is commonly done. Furthermore, many patients continue to receive CaCl2during the initial postoperative period without regard for measured concentrations of ionized calcium, even though normocalcemia may have been restored. Under these conditions of clinical practice, the experimental model used in this study would be both comparable and relevant to the previously demonstrated association between CaCl2administration and pancreatic injury. .

In summary, we were able to demonstrate that infusion of calcium after temporary hypotension can significantly accentuate pancreatic injury caused by temporary hypotension alone. Increased intrapancreatic activation of trypsinogen may be a potential cause of this phenomenon. In the rat, this increased severity of pancreatic morphologic and biochemical damage is associated with significantly higher mortality.

The authors thank Uma Mandavilli, M.S., for technical assistance.

1.
Warshaw AL, O'Hara PJ: Susceptibility of the pancreas to ischemic injury in shock. Ann Surg 188:197-201, 1978.
2.
Rose DM, Ranson JHC, Cunningham JN, Spencer FC: Patterns of severe pancreatic injury following cardiopulmonary bypass. Ann Surg 199:169-172, 1984.
3.
Haas GS, Warshaw AL, Daggett WM, Aretz HT: Acute pancreatitis after cardiopulmonary bypass. Am J Surg 149:508-515, 1985.
4.
Lefor AT, Vuocolo P, Parker FB, Sillin LF: Pancreatic complications following cardiopulmonary bypass. Arch Surg 127:1225-1231, 1992.
5.
Svensson LG, Decker G, Kinsley RB: A prospective study of hyperamylasemia and pancreatitis after cardiopulmonary bypass. Ann Thorac Surg 39:409-411, 1985.
6.
Feiner H: Pancreatitis after cardiac surgery. A morphologic study. Am J Surg 131:684-688, 1976.
7.
Fernandez-del Castillo C, Harringer W, Warshaw AL, Vlahakes GJ, Koski G, Zaslavsky AM, Rattner DW: Risk Factors for pancreatic cellular injury after cardiopulmonary bypass. N Engl J Med 325:382-387, 1991.
8.
MacLean D, Morrison J, Griffith PD: Acute pancreatitis after accidental hypothermia and hypothermic myxedema. Br Med J 4:757-762, 1973.
9.
Murray Wr, Mittra S, Mittra D, Roberts LB, Taylor KM: The amylase creatinine clearance ration following cardiopulmonary bypass. J Thorac Cardiovasc Surg 82:248-253, 1981.
10.
Chenoweth DE, Cooper SW, Hubli TE: Complement activation during cardiopulmonary bypass-evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 304:497-501, 1981.
11.
Klar E, Messmer K, Warshaw AL, Herfarth C: Pancreatic ischaemia in experimental acute pancreatitis: Mechanism, significance and therapy. Br J Surg 70:1205-1210, 1990.
12.
Broe PJ, Zuidema GD, Cameron JL: The role of ischemia in acute pancreatitis: Studies with an isolated perfused canine pancreas. Surgery 91:377-382, 1982, 1983.
13.
Gordon RJ, Ravin M, Rawitscher RE, Daicoff GR: Changes in arterial pressure, viscosity, and resistance during cardiopulmonary bypass. J Thor Cardiovasc Surg 69:552-561, 1975.
14.
Galetti PM, Brecher GA: Heart-lung bypass, Principles and Techniques of Extracorporal Circulation. New York, Grune and Stratton, 1962, pp 194-212.
15.
Cantinella FP, Cunningham JN, Strauss ED, Adams PX, Laschinger JC, Spencer FC: Variations in total and ionized calcium during cardiopulmonary bypass. J Cardiovasc Surg 24:593-602, 1983.
16.
Yokohama H, Julian JS, Vinten-Johansen J, Johnston WE, Smith TD, McGee DS, Cordell AR: Postischemic [Calcium sup 2+] repletion improves cardiac performance without altering oxygen demands. Ann Thorac Surg 49:894-902, 1990.
17.
Shapira N, Schaff HV, White RD, Pluth JR: Hemodynamic effects of calcium chloride injection following cardiopulmonary bypass: Response to bolus injection and continuous infusion. Ann Thorac Surg 37:133-140, 1984.
18.
Robertie PG, Butterworth JF, Royster RL, Prielipp RC, Dudas L, Black KW, Cole LR, Zaloga GP: Normal parathyroid hormone responses to hypercalcemia during cardiopulmonary bypass. ANESTHESIOLOGY 75:43-48, 1991.
19.
Westhorpe RN, Varghese Z, Petrie A, Willis MR, Lumley J: Changes in ionized calcium and other plasma constituents associated with cardiopulmonary bypass. Br J Anaesth 50:951-957, 1978.
20.
Johnston WE, Robertie PG, Butterworth JF, Royster RL, Kon ND: Is calcium or epinephrine superior to placebo for emergence from cardiopulmonary bypass? J Cardiothorac Vasc Anesth 6:528-534, 1992.
21.
Royster RL, Butterworth JF, Prielipp RC, Robertie PG, Kon ND, Tucker WY, Dudas LM, Zaloga GP: A randomized, blinded, placebo-controlled evaluation of calcium chloride and epinephrine for inotropic support after emergence from cardiopulmonary bypass. Anesth Analg 74:2-13, 1992.
22.
Carlon GC, Howland WS, Goldiner PL, Kahn RC, Bertoni G, Turnbull AD: Adverse effects of calcium administration. Arch Surg 113:882-885, 1978.
23.
Fleckenstein A, Janke J, Doring HJ: Key role of calcium in the production of noncoronarogenic myocardial necroses. Rec Adv Stud Cardiol Struct Metab 6:21-31, 1975.
24.
Hosking MP: Should Calcium be administered prior to separation from cardiopulmonary bypass? ANESTHESIOLOGY 75:1121-1122, 1991.
25.
Koski G: Con: Calcium salts are contraindicated in weaning of patients from cardiopulmonary bypass after coronary artery surgery. J Cardiothorac Anesth 2:570-575, 1988.
26.
Steer ML, Meldolesi J: The cell biology of experimental pancreatitis. N Engl J Med 316:144-150, 1987.
27.
Rinderknecht H: Activation of pancreatic zymogens. Normal activation, premature intrapancreatic activation, protective mechanisms against inappropriate activation. Dig Dis Sci 31:314-321, 1986.
28.
Ceska M, Birath K, Brown B: A new and rapid method for the clinical determination of alpha-amylase activities in human serum and urine. Clin Chim Acta 26:437-444, 1969.
29.
Warshaw AL, Bellini CA, Lee KH: Electrophoretic identification of an isoenzyme of amylase which increases in serum in liver diseases. Gastroenterology 70:572-576, 1976.
30.
Fernandez-del Castillo C, Schmidt J, Warshaw AL, Rattner DW: Interstitial protease activation is the central event in the progression to necrotizing pancreatitis. Surgery 116:497-504, 1994.
31.
Hurley PR, Cook A, Jehanli A, Austen BM, Hermon-Taylor J: Development of radioimmunoassays for free tetra-L-aspartyl-L-lysine trypsinogen activation peptides (TAP). J Immunol Methods 111:195-203, 1988.
32.
Schmidt J, Rattner DW, Lewandrowski KB, Compton CC, Mandavilli U, Knoefel WT, Warshaw AL: A better model of acute pancreatitis for evaluation therapy. Ann Surg 215:44-56, 1992.
33.
Moffitt EA, Patrick RT, Swan HJC, Donald DE: A study of blood flow, venous oxygen saturation, blood pressure and peripheral resistance during total body perfusion. ANESTHESIOLOGY 20:18-26, 1953.
34.
Mithofer K, Schmidt J, Gebhardt MM, Buhr HJ, Herfarth C, Klar E: Measurement of blood flow in pancreatic exchange capillaries with FITC-labeled erythrocytes. Microvasc Res 49:33-45, 1995.
35.
Mithofer K, Fernandez-del Castillo C, Frick TW, Foitzik T, Bassi DG, Lewandrowski KB, Rattner DW, Warshaw AL: Increased intrapancreatic trypsinogen activation in ischemia-induced experimental pancreatitis. Ann Surg 221:364-371, 1995.
36.
Spath JA, Gorzcynski RJ, Lefer AM. Pancreatic perfusion in the pathophysiology of hemorrhagic shock. Am J Physiol 226:443-451, 1974.
37.
Mithofer K, Schmidt J, Buhr HJ, Herfarth C, Klar E: Limited microcirculatory compensation of ischemia-induced impairment of pancreatic blood flow (abstract). Gastroenterology 106(suppl):308, 1994.
38.
Sanfey H, Bulkey GB, Cameron JL: The role of oxygen-derived free radicals in the pathogenesis of acute pancreatitis. Ann Surg 200:405-413, 1984.
39.
Opie LH: Reperfusion injury and its pharmacologic modification. Circulation 80:1049-1062, 1989.
40.
Ernster L: Biochemistry of reoxygenation injury. Crit Care Med 16:947-953, 1988.
41.
Cheung JY, Bonventre JV, Malis CD, Leaf A: Calcium and ischemic injury. N Engl J Med 314:1670-1676, 1986.
42.
Krims PE, Pandol SJ: Free cytosolic calcium and secretagogue-stimulated initial pancreatic exocrine secretion. Pancreas 3:383-390, 1988.
43.
Frick TW, Mithofer K, Fernandez-del Castillo C, Rattner DW, Warshaw AL: Intracellular trypsinogen activation is associated with elevated extracellular calcium, but not supramaximal caerulein stimulation in rat pancreatic acini (abstract). Gastroenterology 106(suppl):293, 1994.
44.
Layer P, Hotz J, Eysselein VE, Jansen JBMJ, Lamers CBHW, Schmitz-Moormann HP, Goebell H: Effects of acute hypercalcemia on exocrine pancreatic secretion in the cat. Gastroenterology 88:1168-1174, 1985.
45.
Elz JS, Panagiotopulos S, Nayler WG: Reperfusion-induced calcium gain after ischemia. Am J Cardiol 63:7-13, 1989.
46.
Henry PD, Schuchleib R, Davis J, Weiss ES, Sobel BE: Myocardial contracture and accumulation of mitochondrial calcium in ischemic rabbit heart. Am J Physiol 233:H677-H684, 1977.
47.
Gudgeon AM, Heath DI, Hurley P, Jehanli A, Patel G, Wilson C, Shenkin A, Austen BM, Imrie CW, Hermon-Taylor J: Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis. Lancet 335:4-8, 1990.
48.
Schmidt J, Fernandez-del Castillo C, Rattner DW, Lewandrowski K, Compton CC, Warshaw AL: Trypsinogen-activation peptides in experimental rat pancreatitis: Prognostic implications and histopathologic correlates. Gastroenterology 103:1009-1016, 1992.
49.
Tessenow W, Kruger B, Busing M, Hopt U, Adler G: Colocalization of anionic trypsin(ogen) and cathepsin B in the human exocrine pancreas (abstract). Digestion 54:126, 1993.
50.
Colomb E, Figarella C: Comparative Studies on the mechanism of activation of the two human trypsinogens. Biochim Biophys Acta 571:343-351, 1979.
51.
Frick TW, Fernandez-del Castillo C, Mithofer K, Rattner DW, Warshaw AL: Calcium accelerates trypsinogen activation (abstract). Gastroenterology 106 (suppl):292, 1994.
52.
Kassell B, Kay J: Zymogens of proteolytic enzymes. Science 180:1022-1027, 1973.
53.
Mithofer K, Fernandez-del Castillo C, Frick TW, Lewandrowski KB, Rattner DW, Warshaw AL: Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat. Gastroenterology 109:239-246, 1995.
54.
Pfeffer RB, Lazarini-Robertson A, Safadi D, Mixter G, Secoy CF, Hinton JW: Gradations of pancreatitis, edematous, through hemorrhagic, experimentally produced by controlled injection of microspheres into blood vessels in dogs. Surgery 51:764-769, 1962.
55.
Bassi D, Kollias N, Fernandez-del Castillo C, Foitzik T, Warshaw AL, Rattner DW: Impairment of pancreatic microcirculation correlates with the severity of acute experimental pancreatitis. J Am Coll Surg 179:257-63, 1994.
56.
Hilgard P: Experimental hypercalcemia and whole blood clotting. J Clin Pathol 26:616-619, 1973.
57.
Noji S, Taniguchi S, Kon H: Spin label study of erythrocyte deformability. Calcium sup 2+ -induced loss of deformability and the effects of stomatocytogenic reagents on the deformability loss in human erythrocytes in shear flow. Biophys J 52:221-227, 1987.
58.
Klar E, Rattner DW, Compton C, Stanford G, Chernow B, Warshaw AL: Adverse effects of therapeutic vasoconstrictors in experimental acute pancreatitis. Ann Surg 214:168-174, 1991.